Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evan R Goldfischer

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
BJU International|September 24, 2010
Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose studyJean-Jacques Wyndaele, Evan R Goldfischer, Jon D Morrow, et al.
The Journal of Sexual Medicine|September 22, 2011
Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trialEvan R Goldfischer, Jeffery Breaux, Molly Katz, et al.
BJU International|January 20, 2011
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension studyCraig F Donatucci, Gerald B Brock, Evan R Goldfischer, et al.
Reviews in Urology|November 27, 2019
Preserving Independent Urology: LUGPA's First DecadeNeal D Shore, Deepak A Kapoor, Evan R Goldfischer, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
BJU International|September 24, 2010
Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose studyJean-Jacques Wyndaele, Evan R Goldfischer, Jon D Morrow, et al.
The Journal of Sexual Medicine|September 22, 2011
Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trialEvan R Goldfischer, Jeffery Breaux, Molly Katz, et al.
BJU International|January 20, 2011
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension studyCraig F Donatucci, Gerald B Brock, Evan R Goldfischer, et al.
Reviews in Urology|November 27, 2019
Preserving Independent Urology: LUGPA's First DecadeNeal D Shore, Deepak A Kapoor, Evan R Goldfischer, et al.
Pageof 2